Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006)

Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.s41.004 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. S41.004-S41.004 ◽

Cited By ~ 4

Author(s):

L. Kappos ◽

E.-W. Radue ◽

P. O'Connor ◽

C. Polman ◽

R. Hohlfeld ◽

...

Keyword(s):

Multiple Sclerosis ◽

Phase Iii ◽

Efficacy And Safety ◽

Term Efficacy ◽

Relapsing Remitting ◽

Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2016.02.002 ◽

2016 ◽

Vol 7 ◽

pp. 102-108 ◽

Cited By ~ 4

Author(s):

Takahiko Saida ◽

Jun-ichi Kira ◽

Yasuhiro Ueno ◽

Naozumi Harada ◽

Toshiyuki Hirakata

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Japanese Patients ◽

Efficacy And Safety ◽

Term Efficacy ◽

Relapsing Remitting ◽

Dosing Regimens ◽

Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): Interim analysis of a phase II extension trial in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8951c5 ◽

2017 ◽

Author(s):

Eva Havrdova

Keyword(s):

Multiple Sclerosis ◽

Phase Ii ◽

Interim Analysis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Extension Trial

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis

Multiple Sclerosis Journal - Experimental Translational and Clinical ◽

10.1177/2055217320907951 ◽

2020 ◽

Vol 6 (1) ◽

pp. 205521732090795 ◽

Cited By ~ 1

Author(s):

T Derfuss ◽

J Sastre-Garriga ◽

X Montalban ◽

M Rodegher ◽

J Wuerfel ◽

...

Keyword(s):

Multiple Sclerosis ◽

Term Efficacy ◽

Relapsing Remitting ◽

Efficacy and Safety of Continuous Fingolimod Treatment for At Least 5 Years in Patients with Relapsing-remitting Multiple Sclerosis: Analysis of Long-term Data

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2018.10.027 ◽

2018 ◽

Vol 26 ◽

pp. 237

Author(s):

L. Kappos ◽

N. Tenenbaum ◽

A. Bhatt ◽

A. Couturier ◽

J. Cohen

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Term Data

0564 Long-term sustained efficacy and safety of subcutaneous (Sc) interferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS): The PRISMS 7–8 year results

Journal of the Neurological Sciences ◽

10.1016/s0022-510x(05)80930-x ◽

2005 ◽

Vol 238 ◽

pp. S242

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Efficacy And Safety ◽

Sustained Efficacy ◽

Relapsing Remitting ◽

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Long-Term Lymphocyte Counts in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B and T Cell Subsets

10.26226/morressier.59a3eda8d462b8028d8950f6 ◽

2017 ◽

Cited By ~ 3

Author(s):

Per Soelberg-Sorensen

Keyword(s):

Multiple Sclerosis ◽

T Cell ◽

T Cell Subsets ◽

Relapsing Remitting ◽

EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8952fe ◽

2017 ◽

Author(s):

Robert T. Naismith

Keyword(s):

Multiple Sclerosis ◽

Open Label ◽

Safety Study ◽

Phase 3 ◽

Relapsing Remitting ◽

Effectiveness and Safety of Long-Term Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease

10.26226/morressier.59a3e8b6d462b8028d8953f4 ◽

2017 ◽

Author(s):

Galina Vorobeychik

Keyword(s):

Multiple Sclerosis ◽

Highly Active ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis ◽

Active Disease